Key result
Short-term atorvastatin administration did not increase the mobilization of very small embryonic-like stem cells (VSELs) or upregulate cardiac SDF-1 early after acute myocardial infarction in mice.
Why the study?
Does short-term atorvastatin enhance the mobilization or recruitment of very small embryonic-like stem cells (VSELs) in a murine model of acute myocardial infarction?
Does short-term atorvastatin enhance the mobilization or recruitment of very small embryonic-like stem cells (VSELs) in a murine model of acute myocardial infarction?
Short-term atorvastatin administration fails to upregulate cardiac SDF-1 and does not enhance the mobilization or recruitment of very small embryonic-like stem cells early after acute myocardial infarction in mice.
Answers are grounded in this paper and cite their sources.
Does not support short-term atorvastatin for VSEL mobilization post-MI; leaves open chronic dosing or other models for stem-cell recruitment.
We have found that short-term statin treatment plus stem cell transplantation in acutely infarcted hearts improves cardiac function because statins promote the efficacy of cellular cardiomyoplasty. Autologous Sca-1(+)Lin(-)CD45(-)(CXCR(+)) very small embryonic-like stem cell (VSEL) mobilization in acute myocardial infarction (AMI) correlates with the preservation of cardiac function. Whether short-term atorvastatin (Ator) can enhance the mobilization or recruitment of VSELs in AMI is still unclear. We divided mice into 4 groups: 1) sham; 2) AMI; 3) AMI+resveratrol (RSV) as a positive control; and 4) AMI+Ator. There was an increase in the circulating VSEL/full population of leukocytes (FPL) ratio 48 hours after AMI, and AMI+RSV increased it further. Ator administration did not increase the VSEL/FPL ratio. The cardiac stromal cell-derived factor-1 (SDF-1) and SDF-1alpha levels were in agreement with the results of VSEL mobilization. One week after AMI, more Sca-1(+)CXCR(+) cells were recruited to the myocardium of AMI+RSV mice but not AMI+Ator mice. Short-term Ator administration failed to upregulate cardiac SDF-1 and could not enhance the recruitment of VSELs early after AMI.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2012) studied Acute Myocardial Infarction. Atorvastatin vs. Sham, AMI control, and AMI+resveratrol was evaluated on Circulating VSEL/full population of leukocytes (FPL) ratio 48 hours after AMI. Short-term atorvastatin administration did not increase the mobilization of very small embryonic-like stem cells (VSELs) or upregulate cardiac SDF-1 early after acute myocardial infarction in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: